PHI, Inc. (NASDAQ:PHIIK) tinted loss of -5.72% (-0.19 points) to US$3.13. The volume of 0.5 Million shares climbed down over an trading activity of 427.32 Million shares. EPS ratio determined by looking at last 12 month figures is -0.4. Over the same time span, the stock marked US$13.39 as its best level and the lowest price reached was US$1.69. The corporation has a market cap of US$42.87 Million.
PHI, Inc. (NASDAQ:PHIIK)’s earnings per share has been growing at a -16.26 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 65.34 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Proteostasis Therapeutics, Inc. (NASDAQ:PTI) is worth US$177.45 Million and has recently risen 4.8% to US$3.93. The latest exchange of 1.08 Million shares is above its average trading activity of 1.05 Million shares. The day began at US$3.75 but the price moved to US$3.75 at one point during the trading and finally capitulating to a session high of US$3.75. The stock tapped a 52-week high of US$10.38 while the mean 12-month price target for the shares is US$13.8.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.54, and a price to sales ratio of 39.43. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 58.8%, it carries an earnings per share ratio of -1.76.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.8.